Return to profile

A little more about Alexander...

 

Alexander Marcus Seifalian is a Professor of Nanotechnology and Regenerative Medicine, and director of Director of UCL Centre for Nanotechnology & Regenerative Medicine at University College London (UCL-CNRM).

He completed his education at University of London and University College London Medical School. He is a Fellow of the Institute of Nanotechnology (FIoN) and Fellow of Society of Biology (FSB), and has published over 321 peer-reviewed research papers, 31 book chapter contributions and 4 families of UK and International patents.

During his career he has led and managed many large projects with multidisciplinary teams with very successful outcomes in terms of commercialisation and translation to patients including: 1) The development and commercialisation of a bypass graft for vascular access for haemodialysis; 2) The development of bioreactors with fluid dynamic systems; 3) Derived non-invasive techniques to monitor shear stress in vivo as well as on cells in a physiological flow circuit using RF ultrasound signalling; 4) Techniques to extract RNA from porous scaffolds; 5) Developed laser activated vascular sealants that have been commercialised for vascular, liver and brain surgery, and 6) As part of an EU grant, he worked on the development of a miniature implantable portal blood pump. His role involved designing the pump for biocompatibility and in vitro and in vivo evaluations.  His current projects have led to the development of cardiovascular implants using nanomaterials and stem cell technology, and the development of organs using tissue engineering and nanoparticles for detection and treatment of cancer. He has also developed a family of nanomaterials and nanocomposite polymers for a range of biomedical applications. He was awarded the top prize in the field for development of nanomaterials and technologies for cardiovascular implants in 2007 by Medical Future Innovation, and in 2009 received a Business Innovation Award from UK Trade & Investment (UKTI) in the Life Sciences and Healthcare category. More recently (2011), he developed a lacrimal drainage conduit, vascular bypass graft, and world first synthetic trachea made from nanocomposite polymers and stem cells and delivered them from the laboratory directly to human patients.

 

He has created a huge amount of media interest for his R&D efforts including a first in man bypass graft, lacrimal duct, trachea and many other medical devices, and has over 380 international media reports cited worldwide.